OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
086890$4235.0056

Isu Abxis Co Ltd

PharmaceuticalsVerified

Isu Abxis has a market price of 4235 KRW and a market cap of 171,749,518,710 KRW, with a price-to-book ratio of 1.5 and a price-to-tangible-book ratio of 1.5. The company's enterprise value to EBITDA is 246.74, and its enterprise value to revenue is 2.98. Despite a current ratio of 1.93, the company's liquidity is assessed as low. Profitability metrics show a return on equity of -9.33% and a return on assets of -6.72%, indicating significant underperformance relative to industry norms. The company's operating income of 685,271,740 KRW is modest compared to its revenue of 56,672,366,050 KRW, and it reported a net loss of 10,678,000,440 KRW. The company's revenue is primarily concentrated in domestic and overseas markets, with no disclosed segment breakdown. Its geographic exposure is not specified in the provided data, but the lack of segment details suggests a need for further analysis of revenue concentration. Growth trajectory is mixed, with a free cash flow of -17,170,352,270 KRW and capital expenditure of -11,128,076,830 KRW. The company's operating cash flow of 11,038,341,360 KRW provides some liquidity, but the negative free cash flow indicates ongoing investment in operations. Risk factors include low liquidity and low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.17 suggests a conservative capital structure, but the net loss and negative return on equity highlight financial instability. Recent events include the latest financial filing, which shows a net loss and negative return on equity. No recent transcripts or filings beyond the financial snapshot are provided, limiting insight into management commentary or strategic shifts.

30-day price · 086890-550.00 (-11.8%)
Low$3810.00High$5090.00Close$4115.00As of12 May, 00:00 UTC
Profile
CompanyIsu Abxis Co Ltd
Ticker086890.KQ
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Isu Abxis Co Ltd develops, manufactures, and sells therapeutic antibodies and proteins, including abcertin, pabagal, and clotinap, primarily in domestic and overseas markets.

Classification. Isu Abxis is classified in the Healthcare economic sector under Pharmaceuticals & Medical Research, with a confidence level of 0.92.

Isu Abxis has a market price of 4235 KRW and a market cap of 171,749,518,710 KRW, with a price-to-book ratio of 1.5 and a price-to-tangible-book ratio of 1.5. The company's enterprise value to EBITDA is 246.74, and its enterprise value to revenue is 2.98. Despite a current ratio of 1.93, the company's liquidity is assessed as low. Profitability metrics show a return on equity of -9.33% and a return on assets of -6.72%, indicating significant underperformance relative to industry norms. The company's operating income of 685,271,740 KRW is modest compared to its revenue of 56,672,366,050 KRW, and it reported a net loss of 10,678,000,440 KRW. The company's revenue is primarily concentrated in domestic and overseas markets, with no disclosed segment breakdown. Its geographic exposure is not specified in the provided data, but the lack of segment details suggests a need for further analysis of revenue concentration. Growth trajectory is mixed, with a free cash flow of -17,170,352,270 KRW and capital expenditure of -11,128,076,830 KRW. The company's operating cash flow of 11,038,341,360 KRW provides some liquidity, but the negative free cash flow indicates ongoing investment in operations. Risk factors include low liquidity and low dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.17 suggests a conservative capital structure, but the net loss and negative return on equity highlight financial instability. Recent events include the latest financial filing, which shows a net loss and negative return on equity. No recent transcripts or filings beyond the financial snapshot are provided, limiting insight into management commentary or strategic shifts.
Key takeaways
  • Isu Abxis has a low liquidity rating despite a current ratio of 1.93.
  • The company reported a net loss of 10,678,000,440 KRW and negative returns on equity and assets.
  • Free cash flow is negative at -17,170,352,270 KRW, indicating ongoing operational investment.
  • The company's capital structure is conservative with a debt-to-equity ratio of 0.17.
  • No immediate liquidity or dilution flags were detected in the latest filings.
  • # RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencyKRW
Revenue$56.67B
Gross profit$30.50B
Operating income$685.3M
Net income-$10.68B
R&D
SG&A
D&A
SBC
Operating cash flow$11.04B
CapEx-$11.13B
Free cash flow-$17.17B
Total assets$158.90B
Total liabilities$44.44B
Total equity$114.46B
Cash & equivalents$22.64B
Long-term debt$19.97B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$56.67B$685.3M-$10.68B-$17.17B
FY-1$60.26B-$7.51B$14.72B$7.48B
FY-2$54.31B$3.89B$3.61B-$1.76B
FY-3$41.17B-$15.30B-$7.25B-$11.98B
FY-4$28.02B-$10.24B$829.9M$3.90B
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$158.90B$114.46B$22.64B
FY-1$160.23B$100.86B$24.94B
FY-2$206.74B$77.19B$96.33B
FY-3$137.27B$64.41B$21.09B
FY-4$151.09B$71.95B$14.35B
PeriodOCFCapExFCFSBC
FY0$11.04B-$11.13B-$17.17B
FY-1$2.54B-$11.88B$7.48B
FY-2-$2.69B-$10.45B-$1.76B
FY-3-$401.7M-$10.17B-$11.98B
FY-4-$5.84B-$1.76B$3.90B
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$10.93B-$8.80B-$10.89B-$10.44B
FQ-1$15.73B$562.2M-$255.3M-$5.36B
FQ-2$22.83B$9.38B$9.23B$9.36B
FQ-3$7.18B-$463.3M-$8.76B-$10.18B
FQ-4$20.64B$2.02B$27.93B$25.08B
FQ-5$8.76B-$439.9M$1.12B$559.7M
FQ-6$14.34B$3.62B$2.05B-$244.6M
FQ-7$16.51B-$12.71B-$16.38B-$17.92B
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$158.90B$114.46B$22.64B
FQ-1$165.68B$120.39B$24.40B
FQ-2$168.82B$107.11B$17.10B
FQ-3$156.46B$97.35B$12.86B
FQ-4$160.23B$100.86B$24.94B
FQ-5$132.30B$73.06B$29.13B
FQ-6$140.59B$70.40B$9.42B
FQ-7$139.33B$61.83B$20.82B
PeriodOCFCapExFCFSBC
FQ0$11.04B-$11.13B-$10.44B
FQ-1$12.57B-$10.37B-$5.36B
FQ-2$2.02B-$3.88B$9.36B
FQ-3-$4.62B-$2.52B-$10.18B
FQ-4$2.54B-$11.88B$25.08B
FQ-5$241.8M-$7.84B$559.7M
FQ-6-$6.29B-$6.09B-$244.6M
FQ-7-$6.40B-$2.61B-$17.92B
Valuation
Market price$4235.00
Market cap$171.75B
Enterprise value$169.08B
P/E
Reported non-GAAP P/E
EV/Revenue3.0
EV/Op income246.7
EV/OCF15.3
P/B1.5
P/Tangible book1.5
Tangible book$114.46B
Net cash$2.67B
Current ratio1.9
Debt/Equity0.2
ROA-6.7%
ROE-9.3%
Cash conversion-1.0%
CapEx/Revenue-19.6%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 1 companies
Metric086890Activity
Op margin1.2%-2.9% medp25 -218.9% · p75 9.6%above median
Net margin-18.8%28.2% medp25 28.2% · p75 28.2%bottom quartile
Gross margin53.8%47.8% medp25 27.6% · p75 68.9%above median
CapEx / revenue-19.6%6.6% medp25 6.6% · p75 6.6%bottom quartile
Debt / equity17.0%271.5% medp25 271.5% · p75 271.5%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-11 00:33 UTC#d87b1245
Market quoteclose KRW 4235.00 · shares 0.04B diluted
no public URL
2026-05-11 00:33 UTC#25b14b42
Source: analysis-pipeline (hybrid)Generated: 2026-05-11 00:35 UTCJob: 97ac0443